India Approves Its First Dengue Vaccine (QDENGA®): Everything Parents & Adults Need to Know

India has achieved a historic milestone in preventive healthcare with the approval of QDENGA® (TAK-003), the country's first dengue vaccine approved for individuals aged 4 to 60 years. With dengue cases rising every monsoon, this approval offers new hope for protecting children and adults from one of India's most common mosquito-borne diseases.

Why Is This Approval Historic?

Dengue affects millions of people globally, and India contributes a significant share of cases each year. Until now, prevention mainly relied on mosquito control, repellents, early diagnosis, and supportive treatment. The approval of QDENGA marks the first opportunity to actively prevent dengue through vaccination.

What is QDENGA?

QDENGA (TAK-003), developed by Takeda, is a live attenuated tetravalent dengue vaccine designed to provide protection against all four dengue virus serotypes (DENV-1, DENV-2, DENV-3 and DENV-4).

Unlike earlier dengue vaccines, QDENGA can be administered regardless of whether a person has previously suffered from dengue, without requiring pre-vaccination blood testing.

Who Can Receive the Vaccine?

• Children aged 4 years and above
• Adolescents
• Adults up to 60 years of age

Dose Schedule

• First Dose
• Second Dose after 3 months

Both doses are essential for optimal protection.

How Effective Is It?

Large international clinical trials have demonstrated encouraging protection against symptomatic dengue and excellent protection against hospitalization caused by severe dengue.

• Approximately 80% protection against confirmed dengue
• Over 90% protection against dengue-related hospitalization during primary follow-up

Understanding the Four Types of Dengue

Dengue is caused by four different virus serotypes. Recovering from one type does not protect against the remaining three. In fact, a second infection with another serotype may increase the risk of severe dengue.

This is one reason why developing an effective dengue vaccine has been scientifically challenging.

Will Vaccination Completely Prevent Dengue?

No.

Vaccination should be combined with mosquito prevention measures including:

• Removing stagnant water
• Using mosquito repellents
• Installing window screens
• Wearing full-sleeved clothing
• Sleeping under mosquito nets where necessary

Who Should Consider Vaccination?

• Children living in dengue-endemic cities
• School-going children
• Adults with frequent mosquito exposure
• Healthcare workers
• Residents of urban and semi-urban regions
• Travellers to dengue-prone locations

Frequently Asked Questions

Can someone who has never had dengue receive the vaccine?

Yes. QDENGA has been approved for eligible individuals regardless of previous dengue infection.

Can adults receive it?

Yes. Individuals between 4 and 60 years are eligible.

Does vaccination replace mosquito control?

No. Mosquito bite prevention remains equally important.

Is it available immediately?

Commercial rollout is expected following launch preparations. Availability may initially be through private healthcare providers.

Expert Opinion from Vaccine Panda

The approval of India's first dengue vaccine represents a major advancement in preventive medicine. Vaccination has the potential to significantly reduce severe dengue and hospitalization when combined with mosquito control measures.

Vaccine Panda will update families as soon as the vaccine becomes commercially available and eligible for booking through our pediatrician-led vaccination network.

---

Disclaimer: This article is intended for educational purposes only and should not replace consultation with your healthcare provider. Vaccination decisions should always be made after discussing your medical history with a qualified physician.